Tarek M Meniawy (Tarek Meniawy)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 13

Top Topics

Top Venues

Nature medicine

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Expert review of anticancer therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Joanne M Jeter, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M Meniawy, Paolo Antonio Ascierto, Alexander M Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, Georgina V Long
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nature medicine (2024)
Joanne M Jeter, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M Meniawy, Paolo Antonio Ascierto, Alexander M Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, Georgina V Long
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nature medicine (2023)
Reinhard Dummer, Philippa Corrie, Ralf Gutzmer, Tarek M Meniawy, Michele Del Vecchio, Celeste Lebbè, Michele Guida, Caroline Dutriaux, Brigitte Dreno, Nicolas Meyer, Pier Francesco Ferrucci, Stéphane Dalle, Muhammad Adnan Khattak, Jean-Jacques Grob, Karen Briscoe, James M G Larkin, Sandrine Mansard, Thierry Lesimple, Massimo Guidoboni, Silvia Sabatini, Erika Richtig, Rudolf Herbst, Maurice Lobo, Margarita Askelson, Paolo Antonio Ascierto, Michele Maio
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Joanne M Jeter, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M Meniawy, Paolo Antonio Ascierto, Alexander M Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, Georgina V Long
Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nature medicine (2023)
Deborah Smith, Kristy P Robledo, Sonia Yip, Michelle M Cummins, Peey Sei Kok, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine I G Coward, Philip Beale, Geraldine Goss, Tarek M Meniawy, Janine Lombard, Amanda B Spurdle, John Andrews, Martin R Stockler, Linda Mileshkin, Yoland C Antill, null null
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). Cancers 15 (1) (2022)
Deborah Smith, Kristy P Robledo, Sonia Yip, Michelle M Cummins, Peey Sei Kok, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine I G Coward, Philip Beale, Geraldine Goss, Tarek M Meniawy, Janine Lombard, Amanda B Spurdle, John Andrews, Martin R Stockler, Linda Mileshkin, Yoland C Antill, null null
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). Cancers 15 (1) (2022)
Deborah Smith, Kristy P Robledo, Sonia Yip, Michelle M Cummins, Peey Sei Kok, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine I G Coward, Philip Beale, Geraldine Goss, Tarek M Meniawy, Janine Lombard, Amanda B Spurdle, John Andrews, Martin R Stockler, Linda Mileshkin, Yoland C Antill, null null
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). Cancers 15 (1) (2022)
Deborah Smith, Kristy P Robledo, Sonia Yip, Michelle M Cummins, Peey Sei Kok, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine I G Coward, Philip Beale, Geraldine Goss, Tarek M Meniawy, Janine Lombard, Amanda B Spurdle, John Andrews, Martin R Stockler, Linda Mileshkin, Yoland C Antill, null null
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). Cancers 15 (1) (2022)
Alistair M Cook, Alison McDonnell, Michael J Millward, Jenette Creaney, Arman Hasani, Michelle McMullen, Tarek M Meniawy, Bruce W S Robinson, Richard A Lake, Anna K Nowak
A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. Expert review of anticancer therapy 21 (5) (2021)
Andreas Obermair, Philip Beale, Clare L Scott, Victoria Beshay, Ganessan Kichenadasse, Bryony Simcock, James L Nicklin, Yeh Chen Lee, Paul Andrew Cohen, Tarek M Meniawy
Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. Journal of gynecologic oncology 32 (6) (2021)
David M O'Malley, Maryna Neffa, Bradley J Monk, Tamar Melkadze, Marilyn Huang, Anna Kryzhanivska, Iurie Bulat, Tarek M Meniawy, Andrea Bagameri, Edward W Wang, Bernard Doger de Speville Uribe, Roberto Hegg, Waldo Ortuzar Feliu, Marek Ancukiewicz, Iwona Lugowska
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (7) (2021)
Gabriela Marsavela, Jenny H J Lee, Leslie Calapre, Stephen Q Wong, Michelle R Pereira, Ashleigh C McEvoy, Anna L Reid, Cleo Robinson, Lydia Warburton, Afaf Abed, Muhammad A Khattak, Tarek M Meniawy, Sarah-Jane Dawson, Shahneen Sandhu, Matteo S Carlino, Alexander M Menzies, Richard A Scolyer, Georgina V Long, Benhur Amanuel, Michael Millward, Melanie R Ziman, Helen Rizos, Elin Solomonovna Gray
Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (22) (2020)
Gabriela Marsavela, Peter A Johansson, Michelle R Pereira, Ashleigh C McEvoy, Anna L Reid, Cleo Robinson, Lydia Warburton, Muhammad A Khattak, Tarek M Meniawy, Benhur Amanuel, Michael Millward, Nicholas K Hayward, Melanie R Ziman, Elin Solomonovna Gray, Leslie Calapre
The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond BRAF Mutant Detection. Cancers 12 (12) (2020)